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SUMMARY Two new cyc/opentenylethylamines were prepared and were sub-
mitted to a pharmacological screening together with some others previously described 
and now reprepared. All compounds exhibited different degrees of depressive ac-
tivity on CNS and good analgesic activity. Compound 5, bearing a phenyl group 
on the carbon atom to which the amino group is connected, appears rather interest-
ing being the most active as analgesic and the least toxic. Compounds 2 and 3 are 
able to antagonize in a certain degree lethal doses of physostigmine and also, respec-
tively, of pentylenetetrazole and strychnine. 
RIASSUNTO Sono state preparate due nuove cic/openteniletilammine che, 
congiuntamente ad altre precedentemente descritte ed ora ripreparate, sono state 
sottoposte ad esame farmacologico. Tutte le sostanze esercitano gradi varianti di 
attivita depressiva suI SNC ed elevata attivita analgesica. 11 composto 5, che con-
tiene un fenife legato al carbonio che porta la funzione amminica, appare di un cer-
to interesse essendo if piu attivo come analgesico ed it menD tossico. I composti 2 
e 3 sono capaci di antagonizzare in discreta misura dosi letali di ]lSostigmina, nonche, 
rispettivamente, di pentitenetetrazolo e di stricnina . 
• 
( *) An account of this work was communicated at the "VI Congresso Nazionale 
delIa Divisione di Chimica Farmaceutica delIa S.C.I."; Alghero, 14-18 October 1986. 
(**) To whom correspondence should be addressed. 
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Introduction 
Amino derivatives of terpenoid structures deserve from a long time a 
large interest for the variety of pharmacological activities that they elicit 
(1-3). Thus, in order to evaluate the effect of replacing the planar benzene 
ring with more or less puckered cycloalkyl moieties, in molecules with 
adrenergic and CNS stimulating activities, two of us prepared in the past 
(4), together with several other compounds, the /3-camphylamine 1 and its 
homologues 2 and 3 [2-amino-l-(2,3,3-trimethylcyclopent-l-en-l-yl)-propane 
and 2-amino-l-(2,3,3-trimethylcyclopent-l-en-l-yl)-butane respectively]. 
Since from a preliminary pharmacological screening of those three 
amines some differences of activity depending from the nature of R were 
apparent, we deemed interesting to undertake a somewhat larger study of 
those compounds and also of the amines with R equal to n-propyl (4) and 
phenyl (5), where the lipophilicity and the steric hindrance on the amino 
function are further increased. 
Scheme 1 
R= H 






The /3-camphylamine 1 was prepared as already described (4) by the 
lithium aluminum hydride reduction of /3-campholenic amide (5). The amines 
2-5 were obtained through the sequence of reactions previously set up for 
the preparation of 2 and 3 (Scheme 2). The a-campholenic nitrile was react-
ed with the suitable alkyl or phenyl magnesium halides (6) and the resulting 
ketones were treated with formamide and formic acid in the experimental 
conditions of the Leuckart reaction. Finally the formylamides 9 were hydro-
lized with hydrochloric acid giving place in the same time to the rearrange-
ment of the carbon skeleton (4). 
The new ketones (8 with R = n-C3H, and C6HS) were characterized 
thorugh the elemental analysis of their semicarbazones and their I.R. and 
NMR spectra. The former spectra exibit bands at 2994 and 800 cm-I due 
to the stretching and deformation vibrations of C-H on the double bond, 
and bands respectively, at 1706 and 1700 cm - I, due to the carbonyl group. 
The NMR spectra show a singlet (poorly resolved triplet) at 0 = 5.22 arising 
from the olefinic proton and multiplets at 0= l.80 and 1.89 respectively, 
due to the cyclic CH bearing the side chain. 
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The formylamines 9 were purified through chromatography on silica 
gel and used without further characterization; their IR spectrum (film) 
showed bands around 1660 cm- ' due to the formyl group. 
The new amino compounds 4 and 5 were characterized as hydrochlo-
rides_ Their IR spectra (KBr) do not exhibit any band attributable to olefin-
ic hydrogen. The rearrangement of the a-campholenic skeleton to the (3-
campholenic one was further supported by the NMR spectra where both 
signals at 0 = 5_22 and 1.89 have disappeared (see experimental part). 
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Chemical experimental section 
Melting points were uncorrected; the mp of the amine hydro chlorides were de-
termined in vacuum sealed capillary tubes. Elemental analyses (C,H,N) were per-
formed at the Microanalytical Laboratory of the Istituto di Scienze Farmaceutiche 
of Genova University; the analytical results were within ±0.3OJo of the calculated 
values. 
IR spectra were recorded with a Perkin-Elmer mod. 297 spectrophotomer, us-
ing liquid samples as film and including solid samples in KBr pellets; NMR spectra 
were taken on a Varian XL - 200 spectrometer, using CDCb as solvent with TMS 
as internal standard. Chemical shifts are given in ppm (0). 
ex-Propyl-and ex-phenyl-campholenones (8; R = nC3H7 and CJiJ) 
The new ketones were obtained following the indications already described (6) 
for the preparation of a-methylcampholenone, starting from 0.15 moles of 
propyl magnesium iodide or phenyl magnesium bromide and 0.1 mole of a-
campholenic nitrile. The crude ketones were distilled several times under reduced 
pressure (b.p. 140-145°C at 0.3 - 0.5 mmHg; air bath temp.) in a bulb to bulb ap-
paratus, to remove as much as possible the unreacted nitrile. In both cases the yields 
were around 40-42070. 
8 with R=n-C3H7; 'H-NMR: O.77(s, 3H; CH3); 0.92(t, 3H, CH3-CH2); O.99(s, 
3H; CH3); 1.52-1. 70(m with superimposed s at 1.62, 5H; CHr CH3 + CH3-C = C); 
1.80 (mc, 1H; CH); 2.15-2.55 (m with superimposed t centered at 2.42, 6H; 3CH2); 
5.22 (s, IH; CH=C). 
Semicarbazone: m.p. 119-120°C (ethanol/water); analysis for C'4H2SN03 
(C,H,N). 
8 with R = C6Hs; 'H-NMR: 0.88(s, 3H; CH3); 1.05(s, 3H; CH3; 1.62(s, 3H; 
CH3-C = C); 1. 89(mc, IH; CH); 2.38(mc, 2H; CHrC = C); 3.00(mc, 2H; > CH-
CHrCO); 5.23(s, IH; CH = C); 7.48(mc, 3H arom); 7.97(mc, 2H arom). 
Semicarbazone: m.p. 170-172°C (ethanol); analysis for C17H23N30 (C,H,N). 
N-Formylamines 9 from Leuckart reaction on ketones 8 
A mixture of ketones 8 (0.05 moles) with formamide (6.75 g; 0.15 moles) and 
99% formic acid (2.3 g; 0.05 moles) was heated at 170°C for 48 hours under a slow 
stream of nitrogen. The working up was as already described (4), but the crude for-
mylamines were chromatographed on silica gel eluting with chloroform. 
The amide 9 with R = n-C3H7 was further purified by distillation under reduced 
pressure (b.p. about 140°C at 0.3-0.5 mmHg; air bath temp.). 
The amide 9 with R = C6HS was not distilled, it was obtained from chromatog-
raphy as a low melting solid whose TLC indicated a single compound. Yields were 
around 60-70%. 
Hydrolysis of N-formylamines: 
2-amino-l-(2,3,3-trimethyl-cyclopent-l-en-l-yl)-pentane (4) and 
l-amino-2-(2,3,3 -trimethyl-cyclopent-l-en-l-yl)-l-phenyl-ethane (5) 
The solution of 0.02 moles of formylamines 9 in 25 ml of ethanol was added 
with an equal volume of 6N HCl and refluxed for 10 hours. The solution was con-
centrated under reduced pressure until a fourth of its initial volume that was restored 
. . 
Cyciopentenyl ethylamines active on cns 1165 
with cold water. The amines 2 and 3 were isolated working up the acid solution as 
already described (4), while in the case of amines 4 and 5 the hydrochlorides sepa-
rated spontaneously as white needles that were collected and crystallized from hot 
water. 
4 Hydrochloride: m.p. 213-214°C; analysis for C!3H25N· HCI (C,H,N). 
IH-NMR (hydrochloride in CDCIJ): 0.92 (t, 3H; CHr CH2); 0.95(s, 3H, CHJ); 
1.00(s, 3H; CHJ); 1.40-1.80(m with superimposed s at 1.55, 9H; 3CH2 + CHJ-
C = C); 2.18(mc, 2H; CH2-C = C); 2.48(mc, 2H; C = C-CH2-CH-N); 3.28(m, IH; 
> CH-N); 8.33(large s, 3H; + NHJ). 
5 Hydrochloride: m.p. 240-245°C; analysis for C I6H 2JN· HCI (C,H,N). 
IH-NMR (hydrochloride in CDCb): 0.70(s, 3H; CHJ); 0.89(s, 3H; CHJ); 1.23(s, 
3H; CHrC = C); 1.47(t, 2H; CH2-C(CHJ)2); 1.92(mc, 2H; CHTC = C); 2.71 (mc, 
2H; C=C-CH2-CH-N); 4.21(mc, IH; >CH-N); 7.27(mc, 3H arom); 7.42(mc, 2H 
arom); 8.76(broad s, 3H; -NH+ J). 
Amine hydro chlorides 
For the pharmacological screening the amines 1,2 and 3, that were isolated as 
oily free bases, were converted in their hydrochlorides. They were dissolved in the 
stoichiometric volume of IN ethanolic HCI and the solution was evaporated to dry-
ness under reduced pressure. The residue was dissolved in the minimum volume of 
absolute ethanol and the salt was precipitated with dry ether. 
Pharmacology 
On the five amines 1-5 the following investigations have been worked 
out: LD50' explorative activity, motor coordination, antinociceptive proper-
ties (peripheral and central, with writhing and hot plate test), antagonism 
against physostigmine, strychnine and pentylenetetrazole toxicities. 
Material and methods 
For all the above mentioned tests, female Swiss albino mice were used. The 
animals, weighing 18-22 g, were fasting from 12 hours before tests but with free 
access to water and housed at constant temperature (20-22°C). The test compounds 
as hydro chlorides were administred per os (through a stomach tube) dissolved or 
suspended in a 1 % methylcellulose solution (0.25 ml/lO g body weight), 60 minutes 
before tests. 
Acute toxicity 
For each scalar dose, groups of ten animalss were used; these were close ob-
served during 6 hours from treatment to detect the symptomatology elicited from 
the test compounds. Thereafter the animals were observed for a total of 48 hours 
and at end of this time the mortality was detected and LDso was calculated with 
the Sperman-Karber method (7). 
Explorative activity 
It was detected with the Boissier and Simon test (8) using a square board 37 
cm wide with 16 equidistant holes (2.2 cm diameter), on which each animal was kept 
• 
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for 5 minutes and the explored holes were counted. Compounds were administered 
at the dose of 50 mg/kg using 5 mice. Control animals received only methylcellu-
lose solution. Diazepam (5 mg/kg p.os) was used as reference drug. 
Motor coordination (Muscle relaxing activity) 
This activity was evaluated with the Kinnard and Carr (9) method. using a 
"Rotarod" apparatus (U. Basile, Milano) turning at 16 rpm. Six hours before dos-
ing, animals were selected; only those remaining on the turning rod for more than 
120 seconds were utilized. To these animals (5 for each compound) the test substances 
were given at the dose of 50 mg/kg one hour before the test. Mice that remained 
on the turning rod for less than 2 minutes were considered incoordinate. Diazepam 
(5 mg/kg p.os) was used as reference agent. 
Antinociceptive activity 
a) Writhing test. The method of Sigmund et al. (10) was used with minor modifi-
cations. To groups of 8 animals the test compounds were administered p.os at two 
dose levels (25, 50 or 100 mg/kg, depending on toxicity). The control group received 
only the methylceIIulose solution. After 1 hour to each mouse was injected i.p. 0.1 
mIllO g body weight of 0.25070 solution of formic acid. The writhings of each animal 
were recorded for 20 minutes starting from the injection of the algesic agent. The 
antinociceptive activity was expressed as the % reduction of writhings number com-
pared to that of the control animals. 
b) Hot plate test. The method of Woolfe-McDonald (11) was used, employing 
10 animals for each dose (25,50, 100 mg/kg) of each compound. The animals were 
placed on a stainless steel plate heated at 55 ±0.5°C and mean reaction time was 
determined for each group of mice just before the administration of the test com-
pounds and 1, 2 and 3 hours after the dosing. The percent reaction time variations 
were referred to initial values. The animals with an initial reaction time superior 
to 10 sec were discarded. 
For both anti nociceptive tests morphine was used as reference drug at the dose, 
respectively, of 6.25 and 12.5 mg/kg p.os. 
Protective effects against physostigmine, strychnine and 
pentylenetetrazole toxicities 
For all these tests, groups of 5 mice were used, each receiving a dose ranging 
from 12.5 to 100 mg/kg p.os one hour before the i.p. injection of the convulsant 
agents. 
a) Antiphysostigmine activity. The method of Nose and Kojima (12) was used 
and physostigmine salicylate (corresponding to 0.75 mg/kg of base) was injected. 
The number of surviving animals was counted 60 minutes after the injection of the 
acetylcholinesterase inhibitor. Atropine sulfate (5 mg/kg of base, p.os) was used 
as reference drug. 
b) Antistrychnine activity. The protection from a rapidly lethal dose of strych-
nine nitrate (2.5 mg/kg of base), was evaluated with the Morpurgo method (13). 
The surviving animals 5 minutes after the i.p. injection of strychnine were counted. 
c) Antipentylenetetrazole activity. It was evaluated with the method of Desmedt 
et al. (14) slightly modified; the surviving animals 15 minutes after the i.p. injection 
of 100 mg/ kg of pentylenetetrazole were counted. 
, " 
,-. 
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For tests b) and c) diazepam (10 mg/ kg; p.os) was used as reference substance. 
Results and discussion 
The results of the pharmacological screening on cyclopentenylethyla-
mines 1-5 are illustrated in Tables I-V. It is worthy to note that all com-
pounds were rather toxic (oral LDso between 83 and 332 mg/kg) and were 
generally endowed with CNS depressant activity, although these properties 
do not seem to be correlated to each other. Infact, in compounds 2, 3 and 
4 by increasing the aliphatic chain length the toxicity was lowered while the 
CNS depressant activity was progressively more intense and long lasting, 
as it was observed during the DLso determination (decreased spontaneous 
activity, hypotonicity, ataxia, ptosis) and in the explorative activity, motor 
coordination and central analgesic tests (Tables 11 and IV). 
The compound 1 exibited a depressive symptomatology comparable with 
that of the homologue 2, but it was much less toxic probably on account 
of the easier oxidative metabolism of the unhindered aminogroup. On the 
other hand the compound 5 containing a benzene ring was the least toxic 
and the least active as CNS depressant, so far the motor activity and coor-
dination were considered, while it was very active as analgesic. 
Concerning the antinociceptive activity it is worth noting that all com-
pounds exhibited some degree of analgesia in both used tests; the activity 
against a chemical stimulus (peripheral analgesia) was stronger in compounds 
2 and 3, while that against a thermic stimulus (central analgesia) was higher 
in compounds 4 and 5. Particulary the compound 5 deserves further inves-
tigations for its high and long lasting analgesic activity joined with a moderate 
toxicity. Actually, this amine shows some structural analogies with l-amino-
1 ,2-diphenylethane (15,16) and with lefetamine (17,18), a well known cen-
tral analgesic, where a benzene ring is replaced by a cyclopentene nucleus. 
Finally we mention some degree of protection against lethal doses of 
physostigmine, strychnine and pentylenetetrazole although the protective ac-
tivities were not always dose dependent (Table V). 
Thus the compound 2 at 25 mg/kg antagonized physostigmine (4 sur-
vivors/5) and pentylenetetrazole (3/5), while compound 3 at 50 mg/kg par-
tially antagonized physostigmine (3/5) and strychnine (2/5). 
Without excluding the possibility that the antagonism to physostigmine 
is the result of non specific mechanism, as established in several cases by 
Niemegeer et al. (19) it seems worthwhile to investigate if such activity of 
the amines 1-5 is expression of a central anticholinergic activity that could 
be very interesting as prerequisite for antiparkinson activity. 
Concluding, the results of these preliminary assays support our interest 
on these cyclopentenylethylamines, whose pharmacogenic potentialities will 
be further investigated. 
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TABLE I 
Oral acute toxicity of amines 1-5 
Compounds R 
• 
LD50 ( 95% confidence limits) 
mglkg, 2. os 
1 H 260.0 ( 268.5 -
• 
251. 6 ) 
2 CH3 83.2 ( 95.2 - 72.6 ) 
3 C2 H5 172 .8 ( 194.6 - 153.4 ) 
4 n-C3H7 304.8 ( 355.3 - 261.4 ) 
5 C6 H5 332.3 ( 384.4 - 287.2 ) 
TABLE II 
eNS activities of amines 1-5 
Explorative activity M uscle relaxing 
aotlvlty 
Compounds % of Mean number Variation IncoordInate anImals! 
(SO mg/kg'I!'~ LDSO of explored holes % treated animals ± s.e. 
Controls 43.4 ± 1.25 0 I 5 
Diazepam(a) 7.6 + 1. 77 -82 5 I 5 
-
1 19,2 22.4 + 2.54 -48 2 I 5 
-
2 60,1 18.4 ± 2.72 -57 2 I 5 
3 28,9 6.0 + 1.22 -86 3 / 5 
-
4 16,4 3.75 + 0.62 -91 5 / 5 
-
5 15,0 31.8 + 3.21 -26 0 I 5 -














































Number of writhings at the indicated time after formic acid 
injection ± S.e. ( % variation compared to controls) 
S' 10' lS' 20' 
5.25±0.45 13.25±1.12 18.35±1.60 23.67±1.89 
0.87±0.29 2.50!0.80 3.50±0.73 4.75±0.99(-80) 
1. 57±0. 57 5.00±1.29 7.57±1.87 9.17±2.34(-61) 
1.12±0.66 4.25±1.70 7.00±2.28 7.75±2.44(-67) 
1.25±0.49 4.63±1.08 7.2511.39 8.75±1.85(-63) 
0.14±0.14 1.28±0.74 3.28±1.37 4.14±1.79(-82) 
1.25±0.97 2.75±1.37 4.75±2.08 6.00±2.63(-75) 
0.62±0.26 1.2510.45 1. 50±0. 49 1.62±0.56(-93) 
0.37±0.18 3.37±1.06 7.12±1.44 9.75±1.73(-59) 
0.25±0.16 I 3.12±0.91 7 .25±1. 78 10.00±2.39(-58) 









































1 I 100 
2 I 25 
2 I 50 
3 I 50 
3 I 100 
4 I 50 
5 I 50 
5 I 100 
TABLE IV 
Antinociceptive activity of amines 1-5 (Hot plate test) 
Reaction time ( in sec.) ± s.e. after the indicated hours from 
treatment ( % variation compared to the initial reaction time ) 
0' lh 2h 3h 
I 8.75±0.64 I 8.98±0.43 (+ 3) 10.49±0.66 (+20) 11.32±0.44 (+ 29) 
8.2l±0.50 13.97±1.39 (+70) 14.08±1.04 (+71) 16.62±0.89 (+102) 
8.57±0.48 12.63±0.96 (+47) 13.08±1.14 (+53) 11.75±1.48 (+ 37) 
I 7.42±0.46 I 8.23±0.94 (+14) 11.75±1.38 (+58) 12.68±0.76 (+ 71) 
I 8.57±0.48 I 8.38±0.62 (- 2) 11.70±0.77 (+36) 11.06±0.75 (+ 29) 
I 8.31±0.32 I 12.33±1.28 (+48) 14.93±1.34 (+80) 13.15±1.55 (+ 58) 
I 8.64±0.43 I 12.92±0.73 (+49) 14.32±1.29 (+66) 11.80±0.85 (+ 36) 
I 8.07±0.42 I 15.37±1.19 (+90) 16.03±1.20 (+99) 14.86±1.21 (+ 84) 
I 8.75±0.22 I 15.87±3.75 (+81) 15.59±0.88 (+78) 16.00±1.19 (+ 83) 
I 7.65±0.53 I 14.95±1.19 (+95) 14.15±1.16 (+85) 16.77±0.90 (+119) 
I 7.98±0.45 I 15.46±1.27' (+94) I 15.48±1.40 (+94) I 14.02±1.15 (+ 76) 


























Protective effect of the pretreatment with amines 1-5 against drug toxicity 
Dose 
( mg/kg ) 
~. os 













Surviving animals / treated animals 
after i.p. administration of 
physostigmine 












































( a ) For \ of LD50 see Table III 



























1172 A. MULE et al. 
Acknowledgment 
The financial support from the "Ministero della Universita e della Ricer-
ca Scientijica e Tecnologica" and from "e.N.R." is gratefully ac-
knowledged. 
REFERENCES 
1) MARTIN-SMITH M., KHATOON T., Progress in Drug Research, 6, 279; 1963. 
2) MARTIN-SMITH M., SNEADER W.E., Progress in Drug Research, 13, 11; 1969. 
3) BUCHBAUER G., ESTERER S., CERNAK C., Die Pharmazie, 38, 151; 1983. 
4) PIRISINO G., SPARATORE F., Il Farmaco, Ed. Sci., 27, 480; 1972. 
5) SPARATORE F., PIRISINO G., Gazz. Chim. Ital., 95, 546; 1965. 
6) PIRISINO G., SPARATORE F., Ann. Chim., 62, 113; 1972. 
7) CAVALLl-SFORZA L., "Analisi statistica per medici e biologi", Ed. Boringhieri, Tori-
no,1961;p.173. 
8) BOISSIER J.R., SIMON P., Arch. Int. Pharmacodyn., 147, 372; 1964. 
9) KINNARD W.J., CARR C., J. Pharmacol. Exp. Ther., 121, 354; 1957. 
10) SIEGMUND E., CADMUS R., LU G., Proc. Soc. Exp: Bioi. Med., 95, 729; 1957. 
11) WOOLFE G., Mc DONALD A.D., J. Pharmacol., 80, 300; 1944. 
12) NOSE T., KOJIMA M., Europ. J. Pharmacol., 10, 83; 1970. 
13) MORPURGO C., Arzneim. Forsch., 21, 1727; 1971. 
14) DESMEDT L.K.C., NIEMEGEERS C.J .E., LEVI P .I., JANSSEN P .A.J., Arzneim. 
Forsch., 26, 1592; 1976 .. 
15) HOLCK H.G.O, KIMURA K.K., KIMURA T.E., J. Am. Pharm. Ass, 39, 354; 1950. 
16) NATSUKA K., NAKAMURA H., UNO H., UMEMOTO S., J. Med. Chem., 18, 1240; 
1975. 
17) OOlU K., FUJIMURA H., YAMAKAWA Y., Yakugaku Zasshi, 80, 283; 1960; Chem. 
Abstr., 54, 18426; 1960. 
18) Drug of Today, 19, 82; 1983. 
19) NIEMEGEER C.J.E., AWONTERS F., LENAERTS F.M., VERMEIRE J., JANSSEN 
P .A.J., Arch. Int. Pharmacodyn., 259, 153; 1982. 
Received May 6; 1992; accepted June 5, 1992. 
